16.49
Schlusskurs vom Vortag:
$16.35
Offen:
$16.54
24-Stunden-Volumen:
654.41K
Relative Volume:
1.17
Marktkapitalisierung:
$993.94M
Einnahmen:
$1.23M
Nettoeinkommen (Verlust:
$-214.90M
KGV:
-4.0003
EPS:
-4.1222
Netto-Cashflow:
$-151.25M
1W Leistung:
+7.71%
1M Leistung:
+9.86%
6M Leistung:
-24.43%
1J Leistung:
-46.43%
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie SYRE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SYRE
Spyre Therapeutics Inc
|
16.49 | 924.01M | 1.23M | -214.90M | -151.25M | -4.1222 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
2024-09-04 | Eingeleitet | Wedbush | Outperform |
2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-12-20 | Eingeleitet | BTIG Research | Buy |
2023-12-11 | Eingeleitet | Guggenheim | Buy |
2023-12-11 | Eingeleitet | Jefferies | Buy |
2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
2019-03-21 | Eingeleitet | JP Morgan | Overweight |
2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Is Spyre Therapeutics Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com
Spyre Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com
What analysts say about Spyre Therapeutics Inc. stockTremendous growth potential - jammulinksnews.com
What drives Spyre Therapeutics Inc. stock priceFree High-Return Strategy Alerts - jammulinksnews.com
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $53.40 - Defense World
Why Spyre Therapeutics Inc. stock attracts strong analyst attentionMomentum Swing Watchlist - beatles.ru
How Spyre Therapeutics Inc. stock performs during market volatilityPredictable High Return Trades - Newser
What makes Spyre Therapeutics Inc. stock price move sharplyPotential Rocket List - Newser
Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation - Yahoo Finance
Spyre Therapeutics Announces Grants of Inducement Awards - TradingView
GAMMA Investing LLC Purchases New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Spyre Therapeutics (SYRE) - The Globe and Mail
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha
Spyre reports results from early stage TL1A antibody trials (SYRE) - Seeking Alpha
Transcript : Spyre Therapeutics, Inc.Special Call - MarketScreener
Spyre Therapeutics Announces Positive Interim Phase 1 Results fo - GuruFocus
Spyre Therapeutics Says Anti-TL1A Antibodies Met Objectives in Interim Phase 1 Study - MarketScreener
Spyre Therapeutics Announces Positive Phase 1 Results - TipRanks
Spyre Therapeutics (SYRE) Advances Clinical Trials with Encouraging Interim Results | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PR Newswire
Spyre Therapeutics to Host Conference Call and Webcast to Report - GuruFocus
Spyre Therapeutics to Unveil First Human Trial Data for Revolutionary IBD Antibody Treatment - Stock Titan
Bank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
California State Teachers Retirement System Grows Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Transcript : Spyre Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener
Spyre Therapeutics Announces Grants of Inducement Awards | SYRE Stock News - GuruFocus
Spyre Therapeutics Expands Team with Strategic Stock Options Worth $773K to Three Key Hires - Stock Titan
Squarepoint Ops LLC Purchases 6,754 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Transcript : Spyre Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com
Guggenheim reiterates Buy rating on Spyre stock citing pipeline progress By Investing.com - Investing.com Canada
Spyre Therapeutics to Participate in Upcoming June Investor Conferences - Eastern Progress
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know - sharewise
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):